Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq) to standard-of-care concurrent chemoradiation for limited-stage small-cell lung cancer were reported at the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not improve overall survival (OS) for this patient population.
At the same time, an exploratory analysis reported a longer median OS among patients who received twice-daily radiation, though the RT schedule was not randomized. As a follow-up to that study, a patient-reported outcomes (PRO) analysis explored the impact of the NRG-LU005 treatment regimens on quality of life (QOL). The results of this PRO analysis are now published in the Journal of Thoracic Oncology after previously being reported as a late-breaking abstract at the ASTRO 2025 Annual Meeting in San Francisco.
Although NRG-LU005 results did not meet the study's primary endpoint regarding OS, an incidental finding indicated that twice-daily radiation was associated with longer survival than once-daily radiation. While the study was not randomized between twice-daily and once-daily radiation, the NRG-LU005 PRO analysis also suggested less clinically meaningful decline in longer-term QOL with twice-daily radiation, compared with once-daily radiation, in a cohort of participants who completed PRO surveys.
